Is Stage 3 Brain Cancer Considered Curable?

Stage 3 (grade 3) brain cancer is not considered curable by most oncologists, but that single word obscures a wide spectrum of outcomes. Some grade 3 brain tumors carry a median survival measured in years, not months, and a subset of patients with favorable molecular profiles survive a decade or longer after diagnosis. The gap between the best-case and worst-case scenarios within “grade 3” is so large that the grade number alone tells you surprisingly little about what to expect.

Why “Grade 3” Is Not One Disease

Brain tumors are graded on a scale from 1 to 4 based on how abnormal the cells look under a microscope and how aggressively they grow. Grade 3 tumors are classified as “anaplastic,” meaning the cells are dividing rapidly and look distinctly abnormal, but they have not yet acquired all the hallmarks of a grade 4 tumor (the most aggressive category, which includes glioblastoma). Grade 3 tumors include anaplastic astrocytomas, anaplastic oligodendrogliomas, and certain rarer types like grade 3 meningiomas and ependymomas. Each of these behaves quite differently.

The 2021 overhaul of the World Health Organization’s brain tumor classification system made molecular features just as important as what the cells look like. Two tumors that appear identical under a microscope can now be classified differently if they carry different genetic mutations. This shift happened because those mutations predict survival far more reliably than the tumor’s appearance alone.

Molecular Markers That Change Everything

If you take away one thing from this article, it should be that the molecular profile of a grade 3 brain tumor matters at least as much as the grade itself. Three markers stand out.

The first is a mutation in a gene called IDH (isocitrate dehydrogenase). Tumors carrying an IDH mutation tend to grow more slowly and respond better to treatment. In a large retrospective study of grade 2 and grade 3 astrocytomas, two-year survival was about 95% for patients whose tumors had an IDH mutation, compared with roughly 51% for those without one.¹ That difference is enormous and has led some researchers to argue that IDH status is more meaningful than the grade number itself.

The second marker is a combined deletion of chromosome arms 1p and 19q, called 1p/19q codeletion. This genetic signature defines oligodendrogliomas and is linked to substantially better treatment responses and longer survival. One study following patients with 1p/19q-codeleted tumors treated with upfront chemotherapy reported about an 80% survival rate at 15 years, regardless of whether the tumor was grade 2 or grade 3.² That is a remarkable number for any cancer diagnosis, let alone one labeled “stage 3 brain cancer.”

The third marker is MGMT promoter methylation. MGMT is a DNA repair enzyme, and when the gene that produces it is silenced through a chemical process called methylation, the tumor becomes more sensitive to temozolomide, one of the main chemotherapy drugs used against brain tumors.³ MGMT status can also guide decisions if the tumor comes back: clinicians are more likely to retry temozolomide in recurrent tumors that still show high methylation levels.⁴

The practical upshot is that a grade 3 oligodendroglioma with IDH mutation, 1p/19q codeletion, and MGMT methylation has a prognosis that looks nothing like a grade 3 astrocytoma without an IDH mutation. Treating them as the same disease because they share a grade number would be like treating a sprained ankle and a fractured femur the same because both involve leg pain.

How Surgery Shapes Outcomes

Surgery is almost always the first step when a grade 3 brain tumor is accessible. The goal is to remove as much of the tumor as safely possible without damaging critical brain functions like speech, movement, or vision. The extent of that removal has a meaningful effect on how long patients survive.

Research on diffuse gliomas, including grade 3 tumors, has consistently shown that leaving less residual tumor behind improves survival in a continuous fashion: the less tumor remains, the better the outcome. This relationship holds for patients with and without IDH mutations.⁵ Patients whose scans show no detectable tumor after surgery tend to do particularly well.

For grade 3 astrocytomas specifically, one study found that patients who had a gross total resection (meaning the surgeon removed all visible tumor) had a median survival of about 58 months, compared to 34 months for those who had only a partial removal.⁶ That roughly two-year difference underscores why neurosurgeons push for maximal safe resection when the tumor’s location allows it.

But “safe” is the key qualifier. Many grade 3 tumors grow in parts of the brain that control language, motor function, or other essential abilities. In those cases, the surgeon may deliberately leave some tumor behind to preserve quality of life. The decision involves real tradeoffs, and it is one of the most important conversations patients and their surgical teams will have.

Radiation and Chemotherapy After Surgery

Nearly all patients with grade 3 brain tumors receive radiation therapy after surgery, often combined with chemotherapy. The standard approach varies by tumor type.

For anaplastic astrocytomas, radiation combined with temozolomide is common, though the evidence that adding temozolomide during radiation specifically improves outcomes for this subtype has been less clear-cut than it was for grade 4 glioblastoma. One retrospective study found a median survival of about 31 months for anaplastic astrocytoma patients treated with radiation, with two-year survival around 58%.⁷

For grade 3 oligodendrogliomas with the 1p/19q codeletion, the picture is more encouraging. A regimen called PCV (procarbazine, lomustine, and vincristine) combined with radiation has produced some of the longest survival times in grade 3 brain cancer. Data from the POLA cohort showed that patients who received PCV with radiation had a five-year survival rate around 89%, compared to about 75% for those who received temozolomide with radiation.⁸ The adjusted analysis confirmed this difference, with temozolomide carrying roughly double the risk of death compared to PCV in that population.

The PCV-versus-temozolomide debate is ongoing. PCV appears to produce more durable responses in codeleted oligodendrogliomas, but it also tends to cause more side effects, including drops in blood cell counts and nausea.⁹ Temozolomide is easier to tolerate and simpler to administer as a pill. A national evaluation found that after adjusting for age and how much tumor was removed, the survival difference between the two regimens was no longer statistically significant in that particular dataset, though the trend still favored PCV.¹⁰ In practice, some oncologists choose PCV for younger, fitter patients and temozolomide for older patients or those less likely to tolerate PCV’s side effects.

Grade 3 Meningiomas Are a Different Story

Not all grade 3 brain tumors are gliomas. Grade 3 (malignant) meningiomas arise from the membranes surrounding the brain rather than from brain tissue itself, and they behave differently. They are rare, aggressive, and tend to recur at high rates even after surgery and radiation.

An international multicenter study of grade 3 meningiomas found a five-year overall survival rate of about 66%, with roughly three out of four patients experiencing a recurrence during follow-up. Male sex and age 65 or older were independently linked to worse outcomes, while postoperative radiation was associated with improved survival.¹¹ The molecular toolkit that has reshaped glioma treatment has been slower to yield actionable targets for meningiomas, making this a particularly frustrating diagnosis.

Why “Cure” Is Such a Difficult Word Here

In most cancers, “cure” means the disease is eliminated and does not come back within a standard follow-up window, typically five years. Brain cancer complicates this definition in several ways.

The blood-brain barrier presents a fundamental drug-delivery problem. This semi-permeable membrane protects the brain from toxins in the bloodstream, but it also blocks many therapeutic molecules from reaching tumor cells. Some brain tumors partially disrupt the barrier in the areas where they grow, creating a patchwork called the blood-tumor barrier where drug penetration is uneven and unpredictable.¹² This means that even when chemotherapy reaches parts of a tumor, other parts may be shielded. It is one of the core reasons brain tumors are harder to eradicate than cancers in more accessible organs.

Diffuse gliomas also grow by sending individual cells outward into surrounding normal brain tissue, well beyond the visible tumor margins. A surgeon can remove everything that shows up on an MRI and still leave behind scattered tumor cells that eventually regrow. This infiltrative growth pattern is the primary reason grade 3 gliomas almost always recur, and why the word “cure” is used so cautiously.

That said, long-term survival is a reality for some patients. The 15-year survival data for 1p/19q-codeleted oligodendrogliomas would qualify as “cured” in many other cancer contexts.² Whether those patients harbor dormant tumor cells that could eventually cause problems decades later remains uncertain, but functionally, many of them are living normal lives for many years after diagnosis.

Telling Recurrence Apart From Treatment Effects

One of the trickier problems in managing grade 3 brain tumors is figuring out what is happening on follow-up brain scans. After radiation and chemotherapy, the treated area of the brain often shows changes on MRI that can look exactly like tumor regrowth. This phenomenon, sometimes called pseudoprogression or treatment-related changes, can trigger unnecessary alarm, additional procedures, or premature switches to second-line therapies.

Standard MRI alone is not always sufficient to distinguish true recurrence from these treatment effects. Specialized PET imaging using a tracer called FET (fluoroethyltyrosine) has emerged as a useful tool in ambiguous cases. One study found that FET PET had a sensitivity of about 92% and a diagnostic accuracy of roughly 87% for telling the two apart when MRI was inconclusive.¹³ This kind of imaging is not available everywhere, and access can be a barrier depending on where you live and where your treatment center is located.

Emerging Therapies Targeting Tumor Biology

The identification of IDH mutations as a defining feature of many grade 2 and 3 gliomas has opened a new front in treatment. IDH inhibitors, originally developed for blood cancers that carry the same mutation, are now being tested in brain tumors. Early results have generated genuine excitement, with some trials showing that these drugs can shrink tumors or slow their growth. Vaccine strategies aimed at the mutant IDH protein and combination approaches pairing IDH inhibitors with immunotherapy are also under active investigation.¹⁴

These therapies represent a shift from blunt-force treatments that damage all rapidly dividing cells toward precision approaches that target what makes the tumor cells abnormal in the first place. Whether they will ultimately move the needle on long-term survival or cure rates remains to be seen, but they offer a biologically grounded reason for cautious optimism, particularly for the IDH-mutant tumors that already carry the better prognosis.

The Financial and Emotional Weight of the Diagnosis

Treatment for a grade 3 brain tumor is lengthy and demanding. It typically involves brain surgery, weeks of daily radiation treatments, months of chemotherapy, and then years of follow-up imaging. Each step carries direct medical costs, and there are substantial indirect costs that are easy to underestimate: travel to specialized centers, lost work income, and the cascading financial effects on family members who step into caregiving roles. Research on high-grade glioma patients has documented a significant and sustained financial impact on both patients and their carers, with costs related to travel, treatment, and the added responsibilities of informal caregiving persisting well beyond the initial treatment phase.¹⁵

The psychological burden is equally substantial. Studies have found depression and anxiety rates as high as 48% in brain tumor patients and up to 40% in their caregivers, with many reporting unmet needs and dissatisfaction with communication from their healthcare providers.¹⁶ Cognitive changes from the tumor itself or from treatment can compound these challenges, making it harder for patients to participate fully in their own care decisions as the disease progresses. Addressing these needs early and proactively, rather than treating them as afterthoughts, can make a meaningful difference in how patients and families experience the treatment journey.

What Anaplastic Oligodendrogliomas Tell Us About the Future

The story of grade 3 oligodendrogliomas is worth dwelling on because it illustrates how dramatically the landscape can shift when biology, treatment, and molecular understanding converge. A study of 95 patients with anaplastic oligodendrogliomas found that those whose tumors carried both IDH mutations and 1p/19q codeletion had median progression-free and overall survival times exceeding four and a half years, and many lived far longer than that.¹⁷ Younger age, frontal lobe location, complete surgical removal, and lower proliferation rates all contributed to better outcomes within this group.

These patients were not “cured” in the strict oncological sense. Most will eventually face recurrence and need further treatment. But many are living a decade or more with good quality of life, working, raising families, and in some cases outliving the statistical models that were built before molecular classification existed. For someone newly diagnosed with a molecularly favorable grade 3 oligodendroglioma, the conversation with their oncologist will sound very different from what they might have feared after reading “stage 3 brain cancer” on a search engine.

The gap between the most treatable and least treatable grade 3 brain tumors is wider than the gap between many entirely different cancer diagnoses. That makes generalized survival statistics for “stage 3 brain cancer” almost misleading when applied to an individual patient. The molecular report, the tumor’s location, the patient’s age and overall health, and the extent of surgical removal all carry far more weight than the grade number alone. Anyone navigating this diagnosis benefits from getting their tumor’s full molecular profile and understanding what it means for their specific situation.